Ivermectin for preventing and treating COVID‐19

M Popp, M Stegemann, MI Metzendorf… - Cochrane Database …, 2021 - cochranelibrary.com
Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the
replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of …

Prevalence, incidence and mortality of delirium in patients with COVID-19: a systematic review and meta-analysis

SC Shao, CC Lai, YH Chen, YC Chen, MJ Hung… - Age and …, 2021 - academic.oup.com
Background Attention should be paid to delirium in coronavirus disease 2019 (COVID-19)
patients, especially older people, since advanced age poses increased risk of both delirium …

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - bmj, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

W Alhazzani, L Evans, F Alshamsi, MH Møller… - Critical care …, 2021 - journals.lww.com
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions
worldwide. Given the rapidly growing evidence base, we implemented a living guideline …

Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report

P Horby, WS Lim, J Emberson, M Mafham, J Bell… - MedRxiv, 2020 - medrxiv.org
ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …

[HTML][HTML] Dexamethasone in hospitalized patients with Covid-19

RECOVERY Collaborative Group - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …

A living WHO guideline on drugs to prevent covid-19

F Lamontagne, M Stegemann, A Agarwal, T Agoritsas… - bmj, 2021 - bmj.com
Clinical question What is the role of drugs in preventing covid-19? Why does this matter?
There is widespread interest in whether drug interventions can be used for the prevention of …

[HTML][HTML] Skeletal muscle wasting and function impairment in intensive care patients with severe COVID-19

MC Andrade-Junior, ICD Salles, CMM de Brito… - Frontiers in …, 2021 - frontiersin.org
Background: Intensive care patients commonly develop muscle wasting and functional
impairment. However, the role of severe COVID-19 in the magnitude of muscle wasting and …

Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians practice points

AS Kaka, R MacDonald, N Greer, K Vela… - Annals of internal …, 2021 - acpjournals.org
An updated version of this article was published on 1 March 2022. Background: Remdesivir
is being studied and used for treatment of coronavirus disease 2019 (COVID-19). Purpose …

Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications

AB Rowaiye, OA Okpalefe… - Journal of …, 2021 - Taylor & Francis
The COVID-19 pandemic constitutes an arduous global health challenge, and the
increasing number of fatalities calls for the speedy pursuit of a remedy. This review …